RxDoctor Payments Data

James Phoenix, MD

Internal Medicine · Tulsa, OKNPI 1649311309

Payments from drug & device makers

$222in general payments, 2019–2025

Across 8 payments — averaging $27.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$99
  • Pharmacosmos Therapeutics Inc.$23
  • Novo Nordisk$20
  • Boehringer Ingelheim$19
  • Merck$19
  • Dexcom, Inc.$15
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$222 in reported general payments places this provider in the 45th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$80,009
Medicare patients
432
Services billed
1,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban139$109,972
OzempicSemaglutide89$88,301
MounjaroTirzepatide58$65,357
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$57,646
XareltoRivaroxaban40$35,774
TrulicityDulaglutide16$20,585
FarxigaDapagliflozin Propanediol16$19,926
JardianceEmpagliflozin18$19,868
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog49$19,119
Breo ElliptaFluticasone/Vilanterol38$17,763
JanuviaSitagliptin Phosphate16$15,652
Atorvastatin Calcium508$11,265
Spiriva HandihalerTiotropium Bromide11$9,677
Rosuvastatin Calcium196$9,641
Incruse ElliptaUmeclidinium Bromide25$9,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$20$88,30189 claims
Boehringer IngelheimJardiance, Spiriva Respimat$19$25,52229 claims
MerckJanuvia$19$15,65216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →